Technology

Huons Reports Preclinical Weight Loss Data for Oral MC4R Drug Candidate

NA EUN-KYUNG
2026-11-18 08:57:02
[NA Eun-kyung, Edaily Reporter] Huons presented preclinical results for HUC1-622, an oral small-molecule drug candidate targeting the melanocortin-4 receptor (MC4R), at ObesityWeek 2026 in the United States.

Huons announced on November 17 that its research was selected as a late-breaking abstract for the annual meeting of The Obesity Society, held November 14–17 in National Harbor, Maryland.

Huons participated in ObesityWeek 2026, held in National Harbor, Maryland, USA, from November 14 to 17. In the photo, a researcher from Huons’ New Drug Development Group is presenting the preclinical study results of the oral MC4R agonist “HUC1-622.” (Source=Huons)


MC4R is a receptor in the hypothalamus that plays a role in regulating appetite and energy balance. Activating this receptor can promote satiety and influence energy metabolism.

Existing approved MC4R-targeting treatments for certain rare forms of obesity are injectable peptide drugs. Huons is developing HUC1-622 as a potential oral alternative.

According to the company, HUC1-622 maintained its activity in the presence of agouti-related peptide (AgRP), a naturally occurring protein that stimulates appetite by inhibiting MC4R signaling.

Preclinical experiments also showed that receptor signaling persisted after treatment was discontinued, suggesting the compound may have prolonged activity. Repeated oral administration reduced body weight and fat in obese animal models.

The company also reported that HUC1-622 demonstrated greater selectivity for MC4R than for MC1R, another melanocortin receptor involved in skin pigmentation.

Activation of MC1R by existing peptide-based MC4R agonists can cause increased skin pigmentation. The company stated that its findings suggest HUC1-622 may carry a lower risk of such effects, although this has not yet been established in humans.

These results are still at the preclinical stage, and Huons has not yet established the candidate’s safety or efficacy in patients.

Huons plans to initially develop HUC1-622 for rare forms of obesity while exploring its potential application in broader obesity treatment. Further studies will assess dose-dependent efficacy and its potential use in combination with GLP-1 receptor agonists or as maintenance therapy.

“HUC1-622 is a drug candidate designed from the outset to address the core challenges of MC4R agonists, which are AgRP resistance, sustained signaling, and receptor selectivity,” said Kyung-mi Park, vice president and head of research and development at Huons.

"We will continue to systematically validate its efficacy and safety in subsequent studies," Park added.

Economy

Corporation

IT·Science

Economy

[37th SRE][Issue] BBB-Rated Market Stifled by the JR and JoongAng Crisis

“The bond market should be a universal channel for corporate financing, but right now it’s like an exclusive social club.”This was the point raised by an advisory committee member during a meeting hel…
2026-11-18 10:30:05

Corporation

'Gyochon Makgeolli' Served at APEC Banquet… Available at the Grand Hyatt Hotel

KYOCHON FOOD&BEVERAGE, operator of the Kyochon Chicken franchise, is expanding its sales channels for traditional Korean liquor by introducing its premium makgeolli, “Eunhwasu: A Night of Stargazing 1…
2026-11-18 09:50:52

IT·Science

K-Games Dominate Google Play's 'Game of the Year' List

Google Play announced the “2026 Best of the Year” on the 18th, highlighting the apps and games that were most popular among users over the past year. In South Korea, Nexon’s “Maple Grow” was…
2026-11-18 11:22:31